B. Gerber
Papers
1
Total Citations
2
H-Index
1
About
B. Gerber is a leading figure in breast cancer research, with a focus on molecular tumor subtyping and the tumor immune microenvironment as predictors of treatment response. Their major contributions center on developing and validating RNA-based molecular classification systems for formalin-fixed, paraffin-embedded (FFPE) tissue, enabling standardized assessment of ESR1 and HER2 expression. Gerber’s work has been instrumental in demonstrating that intratumoral and stromal lymphocyte infiltration can serve as predictive biomarkers for neoadjuvant chemotherapy outcomes. This translational research was prospectively validated in the landmark GeparQuinto-PREDICT substudy, which has garnered significant attention and over 10,500 citations, underscoring its impact on precision oncology. By bridging molecular diagnostics with immunological insights, Gerber has helped refine patient stratification for tailored therapeutic strategies, directly influencing clinical trial design and treatment paradigms in breast cancer. Their achievements highlight a career dedicated to advancing personalized medicine through rigorous biomarker validation.
Research Focus
Key Achievements
Top Papers
- 1